Compare IDEXX Laboratories, Inc. (IDXX) vs Intuit Inc. (INTU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Intuit Inc. — how do they compare? IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B), while Intuit Inc. trades at $302.5 (market cap $81.21B). The key difference: Intuit Inc. is far larger — about 2× IDEXX Laboratories, Inc.'s market cap, and Intuit Inc. pays a 1.82% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and Intuit Inc. for 66 Days on average.
| IDXX | INTU | |
|---|---|---|
Market Cap | $40.43B | $81.21B |
Volume | 692,164 | 5,165,806 |
Sector | Health | Technology |
52-Week High | $766.68 | $683.39 |
52-Week Low | $504.70 | $255.07 |
Typical Hold Time | 46 Days | 66 Days |
Enterprise Value | $41.32B | $82.43B |
Dividend Yield | — | 1.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $519.87, up 2.61% on the day, with a bearish technical signal from moving averages but strong fundamentals including a 25.03% net income margin and consistent earnings beats. Revenue grew to $4.3B in 2025, and the company recently acquired CoVetAI to enhance veterinary workflow intelligence, signaling strategic expansion.
The stock's outlook is supported by robust profitability and analyst consensus, but faces headwinds from technical weakness and potential market volatility. With a $665 price target implying significant upside, the primary risks include competitive pressures and execution of growth initiatives amid economic uncertainties.
Intuit (INTU) trades at $297.24, up 2.56% today, with strong fundamentals including 21.29% net income margin and consistent earnings beats. The stock shows bullish technical signals despite mixed moving averages, with key support at $293 and resistance at $300. Recent news highlights growth in QuickBooks monetization and AI initiatives, though overshadowed by multiple class action lawsuits filed in early September 2026.
Outlook remains positive with analyst consensus target of $379.68 (27.7% upside), supported by robust revenue growth and expanding margins. Key risks include legal overhang from securities litigation and competitive pressures in financial software. Institutional sentiment leans bullish with 60% buy ratings, but investors should monitor lawsuit developments and Q3 2026 earnings due soon.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Intuit Inc.
Intuit is a provider of small-business accounting software (QuickBooks), personal tax solutions (TurboTax), and professional tax offerings (Lacerte). Founded in the mid-1980s, Intuit controls the majority of U.S. market share for small-business accounting and DIY tax-filing software.
Read more on INTU →
